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Phase 3 study examining adjunctive armodafinil for the treatment of a major 
depressive episode associated with bipolar I disorder (NCT01072929). METHODS: 
To assess the safety and efficacy of adjunctive armodafinil 150 mg/day in a 
heterogeneous sample of patients, this 8-week, double-blind, placebo-controlled, 
multicenter study evaluated adult patients with bipolar I disorder who were 
currently experiencing a major depressive episode while taking 1-2 maintenance 
therapies (mood stabilizers and/or second-generation antipsychotics). RESULTS: 
The study was conducted at 70 centers in 10 countries from January 2010 to 
March 2012. Of 786 patients screened, 433 were randomized. Baseline disease 
severity as assessed by mean (SD) IDS-C30 total scores was characteristic of 
moderate depression (43.6 [6.93] and 43.2 [7.76] for the placebo and 150 mg 
groups, respectively). The most common concomitant treatments were 
valproate, lithium, and lamotrigine. Patients in the placebo and armodafinil 150 
mg groups experienced their first depressive episode 13.8 (SD 10.24) and 14.5 (SD 
11.73) years prior to screening, respectively. The number of distinct regimens of 
adjunctive treatments will also be reported. CONCLUSIONS: Because the design 
allowed a wider range of adjunctive maintenance therapies, subjects enrolled in 
this study may be more representative of patients in clinical practice. The 
diversity of therapeutic regimens encountered in this study may improve 
external validity/generalizability without sacrificing assay sensitivity, although a 
large sample size was necessary. Further studies are needed to explore how 
research on bipolar depression treatments can improve external validity by 
employing more inclusive designs without sacrificing assay sensitivity.  
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OBJECTIVES: To improve research productivity in an economic environment 
with limited resources, researchers may need to consider investigator-initiated 
approaches to design cost-efficient studies. A cost function was developed to 
guide decisions about trade-offs to be made in clinical trial design with the 
objective of minimizing cost while achieving a given level of power to detect 
differences in patient-reported outcomes. METHODS: The design and conduct of 
a clinical study was treated as a constrained optimization problem. A cost 
function was developed, a Lagrangian function was constructed, and first-order 
partial derivatives were taken with respect to each choice variable (e.g., number 
of recruitment sites, number of follow-up visits, and study duration). 
Comparative statics analysis was used to examine the changes in the choice 
variables as a result of changes in the exogenous variables. RESULTS: A 
necessary condition to minimize cost while achieving a given power is the 
equivalence of the ratios of the marginal cost associated with increasing each 
choice variable and the marginal change in power associated with each choice 
variable; in other words the same cost per unit of output created by each input at 
the margin. For second-order condition, we made the reasonable assumption 
that increasing the number of participants recruited leads to a decrease in the 
marginal rate of change in the Type II error which holds. Comparative statics 
analysis showed that the increase or decrease in the rate of recruitment, 
expected percent loss to follow-up, and the cost of interventions lead to different 
trade-offs between the marginal cost of conducting the clinical trial and the 
marginal change in the probability of committing a Type II error. CONCLUSIONS: 
In light of funding challenges, researchers could consider the trade-offs required 
to achieve a cost-efficient study for a given level of power using methods from 
economics and optimization.  
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OBJECTIVES: In the absence of suitable health care databases, chart review 
studies can result in tailored datasets suitable for evaluations of burden of 
illness, unmet need and drug utilization and safety. This methodology, however, 
is associated with significant design and operational challenges. METHODS: 
Design and operational parameters of ten recent chart review studies of 
treatment patterns, resource utilization and costs of care, clinical outcomes 
and/or drug utilization and safety conducted in Canada, the United States, and 
western Europe have been summarized. Opportunities, challenges and lessons 
learned have been delineated in detail. RESULTS: Four of these studies were 
categorized as post authorization safety studies, and all but one of these studies 
was mandated by the FDA or EMA. Six of the 10 studies were in oncology, and 
evaluated outcomes in patients who had failed at least one line of 
chemotherapy. Sample size varied from 20 patients to greater than 2000, and the 
number of countries and sites varied from 1-6 and 4 to 375 respectively. Across 
studies, key challenges included delineation of eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time; 
design and local implementation of case ascertainment and sampling frame 
methodologies; and safety reporting in the context of retrospective source data. 
Drug utilization studies evaluating inappropriate or off-label use required careful 
attention to protocol language to minimize response bias, as well as a carefully 
executed operational plan for the identification of prescribers and the collection 
of data from prescribers over time. CONCLUSIONS: Though challenging to 
implement, retrospective chart reviews are frequently necessary to address 
research questions spanning burden and costs of care to drug utilization and 
safety. A series of national and multi-national chart review case studies with 
diverse research objectives highlight common design and operational challenges 
that can be anticipated and overcome.  
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Time and Motion (T&M) studies quantify time-related outcomes. Any given 
intervention process can be broken down into a set of pre-defined tasks for 
repeated observations, allowing estimation of the mean task durations in 
support of health economic analyses. While aiming to achieve robust estimates, 
variability in time measurements remains a main methodological challenge. 
OBJECTIVES: To discuss the importance of handling variability and confounding 
in T&M studies. METHODS: Investigation of the impact of variability on process 
duration begins with the analysis of process flow predictors and particularly the 
identification of potential confounders of process duration. Process-related 
variability can result from differences between countries or centers  
(e.g., geography, institution type) or within centers (e.g., patient characteristics, 
process specifics). Additional variability in time measurements can be due to 
insufficient delineation of tasks and inter-rater differences. RESULTS: Once 
potential sources of variability are identified, it must be decided whether  
a variable is to be minimized or accounted for in the study design relating back 
to the health economics objective of the T&M study. For instance, clear 
delineation of processes to be observed and thorough training help limit  
inter-rater variability. On the other hand, limiting data collection to a 
homogenous sample of centers and patients (i.e., specific patient and process 
characteristics), while minimizing variability in study setting and population, 
can compromise generalizability of the results. In situations where a medical 
intervention can be used to treat a broad range of patient populations with 
distinct clinical characteristics, limiting data collection to a certain subgroup 
means generating results applicable to these patients only. CONCLUSIONS: 
Variability can be controlled through thoughtful study design. However, 
significant confounders should be identified and accounted for to produce valid 
process time estimation. Proper handling of variability in time measurement will 
improve precision of the duration estimates in support of health economic 
analyses.  
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BACKGROUND: With the emergence of systematic reviews for evidence-based 
evaluations in health care, the quantitative methods to synthesize evidence have 
been increasingly developed and used to support decision making Particularly in 
the context of HTA evaluations where both post-marketing and pre-marketing 
data may be considered, the evidence to be synthesized can be sparse or related 
to rare outcomes such as risk outcomes. The Bayesian option has increasingly 
appeared as an unrivalled option for such challenging evidence synthesis cases. 
OBJECTIVES: This work aims at highlighting the strengths and limitations of 
Bayesian meta-analysis and mixed treatment comparisons and at providing 
guidance to doers and users of such evidence syntheses in the context of health 
technology assessment with rare or sparse health outcomes in the real-world 
setting. METHODS: Through a list of case studies in risk or benefit/risk studies 
and simulation-based comparisons, the state-of-the-art Bayesian meta-analytic 
approaches are reviewed, adapted to the context of rare events and evaluated for 
their robustness. Under-reporting of risk outcomes in post-marketing studies is 
accounted for in the Bayesian models and sensitivity to the choice of priors is 
analyzed. RESULTS: Provided thorough validation procedures and careful model 
and prior calibration, the Bayesian framework offers an unrivalled framework for 
evidence synthesis of scarce data, for both direct and indirect comparisons, with 
fair and robust quantification of uncertainty. CONCLUSION: Guidance can be 
derived based on the nature and quantity of data which do impact the methods 
reliability, in order to help practitioners and decision makers in using Bayesian 
meta-analysis and models for scarce data in various country and decision 
settings.  
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Decision aids are increasingly used to support doctors and patients in shared 
health care decision making, yet methods to measure their benefits for economic 
evaluation have received limited attention. Significant non-health benefits such 
as improved patient knowledge, experience and satisfaction may accrue through 
the use of decision aids. These cannot be assessed within the dominant health 
economic framework of cost utility analysis. The objective of this paper is to 
propose a new opportunity cost-based method suitable for assessing the benefits 
of decision aids relative to other interventions in a resource-constrained health 
care system. A literature review to identify how decision aids have been 
evaluated found that economic evaluations are limited. Non-health benefits 
